Nuveen AMT-Free Municipal IF (NEA US) stock market data APIs
11.2862
0.03(0.3%)
as of September 15, 2025
Try our APIs with
free plan!
Nuveen AMT-Free Municipal IF Financial Data Overview
Price chart is built with
Anychart
Prev. Close
11.2862
Open
11.3112
High
11.4858
Low
11.3328
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nuveen AMT-Free Municipal IF data using free add-ons & libraries
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nuveen AMT-Free Municipal IF News
New
Nuveen AMT-Free Quality Municipal Income Fund decrease dividend by -6.8% to $0.068/share
* Nuveen AMT-Free Quality Municipal Income Fund (NYSE:NEA [https://seekingalpha.com/symbol/NEA]) declares $0.068/share monthly dividend [https://documents.nuveen.com/Documents/Nuveen/Default.aspx?un...
CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML
New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla VenturesCHARM’s AI-designed menin inhibitor overcomes resistance mutations with the potential...
CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML
Charm Therapeutics New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla Ventures CHARM’s AI-designed menin inhibitor overcomes resistance mutatio...
CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML
New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla VenturesCHARM’s AI-designed menin inhibitor overcomes resistance mutations with the potential...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
